We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+0.73%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$24.1B
AUM Growth
+$1.97B
Cap. Flow
+$2.05B
Cap. Flow %
8.49%
Top 10 Hldgs %
10.49%
Holding
3,709
New
1,118
Increased
953
Reduced
622
Closed
747

Sector Composition

Rank Sector Weight
1 Healthcare 20.28%
2 Financials 16.56%
3 Technology 13.74%
4 Consumer Discretionary 11.01%
5 Communication Services 4.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GHL
2501
DELISTED
Greenhill & Co., Inc.
GHL
$397K ﹤0.01%
27,162
-22,221
-45% -$331K
ENTG icon
2502
Entegris
ENTG
$16.3B
$396K ﹤0.01%
+3,148
New +$380K
SPR
2503
DELISTED
Spirit AeroSystems
SPR
$396K ﹤0.01%
+8,970
New +$376K
ELVT
2504
DELISTED
Elevate Credit, Inc.
ELVT
$396K ﹤0.01%
95,882
+59,128
+161% +$212K
MSON
2505
DELISTED
Misonix Inc
MSON
$396K ﹤0.01%
+15,635
New +$387K
ACIU icon
2506
AC Immune
ACIU
$231M
$391K ﹤0.01%
58,378
-12,685
-18% -$90.8K
FCEL icon
2507
FuelCell Energy
FCEL
$1.45B
$391K ﹤0.01%
1,950
-11,647
-86% -$2.31M
COLIW
2508
CALL
DELISTED
Colicity Inc. Warrant
COLIW
$391K ﹤0.01%
39,992
ATYR
2509
aTyr Pharma
ATYR
$47.4M
$390K ﹤0.01%
+43,006
New +$257K
SPGS.WS
2510
CALL
DELISTED
Simon Property Group Acquisition Holdings, Inc. Warrants, each exercisable for one Class A common stock at an exercise price of $11.50 per share
SPGS.WS
$390K ﹤0.01%
39,992
KCAC.WS
2511
CALL
DELISTED
Kensington Capital Acquisition Corp. II Redeemable warrants, each whole warrant exercisable for one
KCAC.WS
$389K ﹤0.01%
46,996
+22,000
+88% +$29.1K
MCRI icon
2512
Monarch Casino & Resort
MCRI
$2.2B
$388K ﹤0.01%
5,791
-1,556
-21% -$101K
NE icon
2513
Noble Corp
NE
$6.55B
$388K ﹤0.01%
+14,323
New +$343K
STZ icon
2514
Constellation Brands
STZ
$22.5B
$388K ﹤0.01%
1,841
-24,486
-93% -$5.34M
TTWO icon
2515
Take-Two Interactive
TTWO
$46.1B
$388K ﹤0.01%
2,519
-103,259
-98% -$16.7M
GNR icon
2516
State Street SPDR S&P Global Natural Resources ETF
GNR
$4.75B
$387K ﹤0.01%
+7,546
New +$393K
INZY
2517
DELISTED
Inozyme Pharma
INZY
$387K ﹤0.01%
33,408
-6,794
-17% -$106K
MIXT
2518
DELISTED
MIX TELEMATICS LIMITED
MIXT
$386K ﹤0.01%
31,396
-6,507
-17% -$88.5K
STFC
2519
DELISTED
State Auto Financial Corp
STFC
$386K ﹤0.01%
+7,575
New +$359K
ARTNA icon
2520
Artesian Resources
ARTNA
$360M
$385K ﹤0.01%
10,096
+1,977
+24% +$76K
ENB icon
2521
Enbridge
ENB
$120B
$385K ﹤0.01%
9,658
-684,565
-99% -$27M
ASPC
2522
DELISTED
Alpha Capital Acquisition Co
ASPC
$385K ﹤0.01%
+39,616
New +$384K
CUE icon
2523
Cue Biopharma
CUE
$118M
$384K ﹤0.01%
878
-177
-17% -$61.7K
CONN
2524
DELISTED
Conn's Inc.
CONN
$383K ﹤0.01%
16,768
-49,150
-75% -$1.17M
MOR
2525
DELISTED
MorphoSys AG American Depositary Shares
MOR
$382K ﹤0.01%
32,493
+22,151
+214% +$321K

Similar funds

Marshall Wace's Q3 2021 Portfolio in Review

As of Q3 2021, Marshall Wace held 3,709 positions worth $24.1B, up 8.9% from $22.1B the previous quarter. Its ten largest holdings account for 10% of the portfolio.

Marshall Wace deployed $2.05B of net new capital in Q3 2021, opening 1,118 new positions and adding to 953 existing holdings. Its largest new stake was SkinHealth Systems: 4,113,430 shares worth $107M.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Biogen, an estimated $210M trimmed.

  • Marshall Wace's largest Q3 2021 buy was SkinHealth Systems: 4,113,430 shares worth $107M.
  • Marshall Wace added most to Uber in Q3 2021, an estimated $127M increase.
  • Marshall Wace's biggest Q3 2021 reduction was Biogen, cutting an estimated $210M.
  • Marshall Wace fully exited Vipshop in Q3 2021, selling an estimated $58.7M.
  • Marshall Wace's ten largest holdings make up 10% of its $24.1B portfolio in Q3 2021.
  • Marshall Wace opened 1,118 new positions and closed 747 in Q3 2021.
  • Marshall Wace's portfolio value rose 8.9% quarter-over-quarter to $24.1B.

Based on Marshall Wace's 13F filing for Q3 2021, filed 15 Nov 2021.